Privately owned CDMOs in Europe: 155 compared (2026)
155 of the 255 contract development and manufacturing organisations in A4BEE’s European census are privately owned. The largest, with revenue over €1bn, are ACS Dobfar, Almac Group, Biofarma Group, Biovet (Huvepharma), BSP Pharmaceuticals, ESTEVE (Química / CDMO) and 10 more. 47 sit between €250m and €1bn and 92 are smaller or niche.
By ownership: 101 family-owned and 54 private equity. They are spread across 28 countries, led by Germany (19), Italy (19), the United Kingdom (19), Spain (16) and France (8). 79 of the 155 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
155 companies
Privately owned CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| ACS DobfarItalian anti-infectives specialist (1973). Vertically integrated: cephalosporin/carbapenem/penicillin APIs AND finished dosage on a CDMO basis. | Tribiano, Italy | Family-owned | Tier 1 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | high |
| Almac Group£400 m+ capex program; broad clinical + diagnostics services alongside API. | Craigavon, United Kingdom | Family-ownedMcClay charitable trust | Tier 1 | £1.027 bn FY2024 | Small-molecule API, Peptide, Antibody-drug conjugate (ADC) | high |
| Biofarma GroupItalian/European leader in third-party-exclusive dev, manufacture and packaging of food supplements, probiotic drugs, medical devices. | Mereto di Tomba, Italy | Private equityArdian | Tier 1 | €443.3 m | Oral solid dose | high |
| Biovet (Huvepharma)Huge fermentation platform — mainly own animal-health APIs but offers custom synthesis/fermentation and human-health APIs. CDMO relevance is microbial API. | Peshtera, Bulgaria | Family-ownedHuvepharma / Domuschiev family | Tier 1 | not disclosed | Microbial and protein, Small-molecule API | low |
| BSP PharmaceuticalsLeading oncology CDMO: ADC conjugation + highly-potent aseptic fill-finish from clinical to commercial. Serves ~80 countries. | Latina, Italy | Family-ownedBraca family | Tier 1 | €532.7 m (2024) | Sterile fill-finish, Antibody-drug conjugate (ADC), Monoclonal antibody, Oral solid dose | high |
| ESTEVE (Química / CDMO)Self-described 'Champion Small-Molecule CDMO'; APIs, HPAPIs and advanced intermediates for third parties. | Barcelona, Spain | Family-ownedEsteve family | Tier 1 | not disclosed | Small-molecule API | high |
| F.I.S. Fabbrica Italiana SinteticiOne of the largest small-molecule API CDMOs in the world. Strong GLP-1 growth. Controlled by Bain Capital since 2023. | Montecchio Maggiore, Italy | Private equityBain Capital | Tier 1 | €879 m (2025) | Small-molecule API | high |
| FamarOne of Europe's largest pure-play pharma/consumer-health CDMOs; 70+ yr legacy. Sterile injectables, eye drops, syrups, solids. 80 markets. | Alimos, Greece | Private equityMidEuropa | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| Fareva | Luxembourg, Luxembourg | Family-owned | Tier 1 | ~€2.2 bn | Sterile fill-finish, Oral solid dose, Small-molecule API, Monoclonal antibody | medium |
| HovioneFully integrated specialist CDMO: API, particle engineering/spray drying, drug product. FDA-inspected across 3 continents. | Loures, Portugal | Family-ownedVillax family | Tier 1 | not disclosed | Small-molecule API, Oral solid dose | high |
| Insud Pharma (Chemo)Group-level entity. Chemo industrial division provides CMO/CDMO across most dosage forms incl. injectables. Parent of Liconsa and León Farma. | Madrid, Spain | Family-ownedGrupo Insud | Tier 1 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish, Biologics and biosimilars, Monoclonal antibody | high |
| OlonOne of Europe's largest API CDMOs; absorbed Euticals. Chemical synthesis + microbial fermentation, HPAPI, ADC bioconjugation. | Rodano, Italy | Family-owned | Tier 1 | ~€546 m (2024, group) | Small-molecule API, Microbial and protein, Peptide, Antibody-drug conjugate (ADC), Biologics and biosimilars | high |
| PharmathenVertically integrated developer of complex drug-delivery tech offering CDMO/co-development: long-acting injectables, SR oral solids, ophthalmics. | Pallini, Greece | Private equityPartners Group | Tier 1 | not disclosed | Oral solid dose, Sterile fill-finish, Peptide | high |
| SeqensLarge API/small-molecule CDMO plus specialty ingredients; ~200 APIs. Revenue includes non-pharma specialty ingredients. | Écully, France | Private equitySK Capital | Tier 1 | ~€1.1 bn (group) | Small-molecule API, Peptide | high |
| Vetter PharmaSterile fill-finish specialist (vials, syringes, cartridges). | Ravensburg, Germany | Family-owned | Tier 1 | n/d (large) | Sterile fill-finish | medium |
| Zentiva GroupLarge generics maker with an explicit B2B/CDMO arm (oral solids, sterile ampoules/vials, creams; APIs). Contract offering spans Prague and Bucharest. | Prague, Czechia | Private equityAdvent International | Tier 1 | ~€1.3 bn (group est.) | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| AbzenaIntegrated biologics / bioconjugate / ADC CDMO+CRO, UK-founded but increasingly US-centred — European-HQ status borderline. Fills the ADC/bioconjugation gap. | Cambridge, United Kingdom | Private equityWelsh, Carson, Anderson & Stowe | Tier 2 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC) | low |
| Adamed Pharma | Pieńków, Poland | Family-owned | Tier 2 | >PLN 1.6 bn (2023) | Small-molecule API, Oral solid dose | medium |
| Adragos PharmaFSN Capital 'buy-and-build' roll-up acquiring sites from Sanofi/Fresenius Kabi. | Munich, Germany | Private equityFSN Capital | Tier 2 | n/d | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Aenova GroupMulti-site OSD/softgel/sterile group; acute data-silo profile across 14 sites. | Starnberg, Germany | Family-ownedKühne Holding | Tier 2 | n/d | Oral solid dose, Sterile fill-finish | medium |
| AxploraAPI/HPAPI specialist across German and French sites. | Munich, Germany | Private equity | Tier 2 | n/d | Small-molecule API, Antibody-drug conjugate (ADC) | low |
| BioSpringPrivately held German nucleic-acid CDMO (oligonucleotides — ASO, siRNA, guide RNA — plus mRNA). Fills a modality gap the roster otherwise lacks. | Frankfurt am Main, Germany | Family-owned | Tier 2 | not disclosed | mRNA and LNP, Small-molecule API | medium |
| BluepharmaIntegrated CRDMO. OSD capacity ~2bn units/year plus complex injectables and LNP work. FDA-inspected 5×. | Coimbra, Portugal | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| CambrexSmall-molecule API + continuous flow + liquid-phase peptides; several EU sites. | East Rutherford, NJ, United States | Private equityPermira | Tier 2 | ~US$500 m–1 bn | Small-molecule API, Peptide | medium |
| Cambrex Profarmaco MilanoItalian operating entity of US-HQ Cambrex; generic APIs + custom/contract manufacturing of APIs and intermediates. | Paullo, Italy | Private equityCambrex (Permira) | Tier 2 | not disclosed | Small-molecule API | medium |
| Centrient PharmaceuticalsFormerly DSM Sinochem. Enzymatic beta-lactam antibiotics, statins, antifungals; APIs plus finished dosage and CDMO. | Rijswijk, Netherlands | Private equityBain Capital | Tier 2 | ~€560 m | Small-molecule API, Microbial and protein | high |
| CIPANAPI CDMO via fermentation and chemical synthesis (founded 1960). FDA-approved; anti-infectives, psychotropics. Part of Suanfarma. | Castanheira do Ribatejo, Portugal | Private equitySuanfarma | Tier 2 | not disclosed | Small-molecule API, Microbial and protein | high |
| CordenPharmaPeptide + lipid/LNP specialist riding the GLP-1 boom (e.g. Viking deal). | Basel, Switzerland | Private equity | Tier 2 | ~US$530 m | Peptide, mRNA and LNP, Sterile fill-finish, Small-molecule API | medium |
| Delpharm | Boulogne, France | Family-owned | Tier 2 | ~€650 m | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | medium |
| DEMOPrimarily own-product (largest injectables supplier to Greek hospitals) but lists contract manufacturing. Own-API from 2019. | Krioneri, Greece | Family-owned | Tier 2 | not disclosed | Sterile fill-finish, Small-molecule API | medium |
| Dipharma FrancisGlobal CDMO + generic API manufacturer (>40 APIs) plus exclusive/custom synthesis. FDA-inspected. | Baranzate, Italy | Family-owned | Tier 2 | not disclosed | Small-molecule API | medium |
| Doppel FarmaceuticiFull-service finished-dose CDMO: solids, semi-solids, liquids, sprays, and aseptic/terminally-sterilized injectable vials. | Cortemaggiore, Italy | Private equityTrilantic Europe | Tier 2 | €112.8 m (2024) | Oral solid dose, Sterile fill-finish | high |
| EthypharmHybrid specialty pharma + CDMO; CDMO arm specializes in controlled substances, HPAPIs and modified-release oral. | Saint-Cloud, France | Private equityPAI Partners | Tier 2 | €135 m (2024, SAS) | Oral solid dose, Small-molecule API | medium |
| FarmabiosWorld leader in steroid chemistry (>80 APIs) + CDMO for HPAPIs, cytotoxics, hormones. Italian site of Axplora group. | Gropello Cairoli, Italy | Private equityAxplora | Tier 2 | not disclosed | Small-molecule API | high |
| Farmhispania GroupIndependent private API CDMO; leading European CDMO in HPAPI (cytotoxics) plus fermentation and large-scale lyophilisation. | Montmeló, Spain | Family-owned | Tier 2 | not disclosed | Small-molecule API, Microbial and protein | high |
| FlammaFamily-owned small-molecule API CDMO since 1950; leader in amino acids and peptide building blocks. FDA-inspected. | Chignolo d'Isola, Italy | Family-ownedNegrisoli family | Tier 2 | not disclosed | Small-molecule API, Peptide | high |
| GeneticLeading Italian CDMO in respiratory + ophthalmic. BFS sterile monodose, eye drops, nasal sprays, pMDI/DPI inhalers. | Fisciano, Italy | Private equityRenaissance Partners | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| GrindeksMajor Baltic pharma that formally launched CDMO services (2025): API dev/manufacturing incl. HPAPIs, plus solid/liquid/semi-solid FDFs. Sterile injectables via Kalceks. | Riga, Latvia | Family-ownedKirovs Lipmans (majority) | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| ICE (Industria Chimica Emiliana)World-leading integrated producer of bile-acid APIs (UDCA, TUDCA); custom-CDMO role narrower. Founded 1949. | Reggio Emilia, Italy | Family-owned | Tier 2 | not disclosed | Small-molecule API | medium |
| JGLLargest domestically-owned Croatian pharma and a genuine end-to-end sterile CMO — aseptic eye drops, nasal/bag-on-valve sprays. Expanding sterile capacity through 2026. | Rijeka, Croatia | Family-owned | Tier 2 | not disclosed | Sterile fill-finish | low |
| Kern PharmaDedicated 'Production to Third Parties' line. 3rd-largest Spanish generics producer by volume; chemical plant synthesises APIs. | Terrassa, Spain | Family-ownedGrupo Indukern | Tier 2 | not disclosed | Oral solid dose, Small-molecule API | high |
| LabomarNutraceutical/food-supplement finished-dose CDMO (supplements, medical devices, pharmaceuticals) for third parties. | Istrana, Italy | Private equityCharterhouse Capital | Tier 2 | €135 m (2025) | Oral solid dose | low |
| Laboratorios NormonPrimarily own-product generics leader; offers CMO services via its International Division. CMO is a secondary line. | Tres Cantos, Spain | Family-owned | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish, Small-molecule API | medium |
| Laboratorios SalvatCDMO division specializes in sterile BFS liquids and single-dose ophthalmic/otic/nasal formulations. | Barcelona, Spain | Family-ownedPeris family | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| Meribel Pharma SolutionsFormed 2025 from Synerlab + 7 Recipharm sites; classic multi-site integration play. | London, United Kingdom | Private equityBlue Wolf | Tier 2 | ~€300 m est. | Sterile fill-finish, Oral solid dose | medium |
| MinakemAPI and HPAPI CDMO (custom synthesis). Brand of the privately-held Minafin Group. | Dunkerque, France | Family-ownedMinafin Group | Tier 2 | not disclosed | Small-molecule API | medium |
| Minaris Advanced TherapiesCell & gene therapy CDMO (formerly Minaris Regenerative Medicine / Apceth). Merged with WuXi Advanced Therapies in 2025; Ottobrunn is the European base. | Ottobrunn, Germany | Private equityAltaris Capital Partners | Tier 2 | not disclosed | Cell and gene therapy | high |
| NextPharma | London, United Kingdom | Private equity | Tier 2 | ~€229 m | Oral solid dose, Sterile fill-finish | medium |
| NorthX BiologicsBiologics CDMO built on the former Cobra Biologics Matfors site; Swedish national innovation hub for ATMPs. | Matfors, Sweden | Private equityFlerie Invest | Tier 2 | not disclosed | Microbial and protein, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy, Monoclonal antibody, Sterile fill-finish | low |
| Olainfarm (Olpha)One of the largest Baltic pharma companies (rebranded Olpha); contract manufacturing and co-development across APIs, intermediates and solid FDFs. | Olaine, Latvia | Private equityAB City holding | Tier 2 | not disclosed | Small-molecule API, Oral solid dose | high |
| Quotient SciencesFull-service third-party CDMO (drug substance/product + clinical). UK-HQ under European PE. | Nottingham, United Kingdom | Private equityPermira | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Peptide, Sterile fill-finish | low |
| RafarmEnd-to-end CDMO/CMO (50 yrs); third-party contract manufacturing of sterile ophthalmics and complex injectables (robotic sterile lines). | Paiania, Greece | Family-owned | Tier 2 | not disclosed | Sterile fill-finish | high |
| Recipharm | Stockholm, Sweden | Private equityEQT | Tier 2 | €827 m (2024) | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| Rentschler BiopharmaComplex-protein pure-play; exited CGT in 2025 to refocus on biologics. | Laupheim, Germany | Family-owned | Tier 2 | ~US$296 m (2025) | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | medium |
| Rottendorf Pharma~95-year-old foundation-owned CDMO focused on oral solid dosage forms. | Ennigerloh, Germany | Family-ownedRottendorf Foundation | Tier 2 | not disclosed | Oral solid dose | high |
| Saneca PharmaceuticalsSlovakia's largest pharma and a genuine API + FDF CDMO (carve-out of former Zentiva/Sanofi API business). Opiate/narcotic API specialist plus oral solids. | Hlohovec, Slovakia | Private equity | Tier 2 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| Sever Pharma SolutionsSpecialist CDMO for high-potent (OEB6)/cytotoxic/hormonal drug products and polymer-based delivery. Formerly QPharma. | Malmö, Sweden | Family-ownedNordic Group (Paulsen family) | Tier 2 | not disclosed | Oral solid dose | high |
| Special Product's Line (SPL)Italian CDMO specialized in non-sterile finished dose: oral solids, liquids and semi-solids for 60+ clients. EU-GMP. | Anagni, Italy | Family-owned | Tier 2 | not disclosed | Oral solid dose | high |
| SUANFARMASpain-HQ B2B life-sciences; CDMO offers end-to-end small-molecule dev/manufacturing combining fermentation and synthesis. | Alcobendas, Spain | Private equityArchiMed | Tier 2 | not disclosed | Small-molecule API, Microbial and protein | high |
| Tecnimede (Atlantic Pharma)Primarily own-product/generics group that also offers contract manufacturing (solids/semi-solids/liquids). CMO secondary. | Sintra, Portugal | Family-ownedTecnimede Group | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Unither PharmaceuticalsWorld leader in Blow-Fill-Seal sterile unit-dose liquids; also effervescent/oral formats. | Amiens, France | Private equityArdian | Tier 2 | €371 m (2022) | Sterile fill-finish, Oral solid dose | high |
| Vianex90+ yr firm; long-standing contract manufacturer (exclusive local/export production for MSD since 1983). Cephalosporins + solids/injectables. | Nea Erythraia, Greece | Family-ownedGiannakopoulos family | Tier 2 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| VibalogicsSpecialist virus/viral-vector and oncolytic-virus CDMO; PE-backed. German HQ with a US site added later. | Cuxhaven, Germany | Private equityAmpersand Capital Partners | Tier 2 | not disclosed | Viral vector and vaccine, Cell and gene therapy | high |
| 3PBIOVIANMerger of 3P Biopharmaceuticals (Spain) + Biovian (Finland). | Noáin, Spain | Private equityKeensight | Tier 3 | ~US$81 m | Microbial and protein, Viral vector and vaccine, Cell and gene therapy | medium |
| 53BiologicsSpanish biologics CDMO (2017); recombinant proteins from DNA to protein — cell line dev, banking, GMP manufacturing. | Boecillo, Spain | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein | medium |
| AdipharmPrivately-owned Bulgarian full-service CMO for solid dosage, semi-solids and oral liquids (dev, bulk, packaging incl. serialization). New €3.6M site (2022). | Sofia, Bulgaria | Family-owned | Tier 3 | not disclosed | Oral solid dose | high |
| Anfarm HellasEU-GMP manufacturer offering 3rd-party manufacturing / CDMO / tech transfer. Specializes in lyophilised products, liquid injectables, beta-lactams. | Kifissia, Greece | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| APC / VLE TherapeuticsIrish-founded (UCD spinout). APC = process-dev/CMC; sister VLE runs the GMP 'factory of the future' — the group has genuine manufacturing. | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Biologics and biosimilars, Viral vector and vaccine, mRNA and LNP | high |
| ArdenaNanomedicine/LNP + drug-substance/product + bioanalytical CDMO. | Ghent, Belgium | Private equityGHO Capital | Tier 3 | n/d | mRNA and LNP, Oral solid dose, Sterile fill-finish | medium |
| Bath ASUOne of the UK's largest independent aseptic 'specials' manufacturers — patient-specific chemo, CIVAS, PCA injectables for 220+ NHS trusts. | Corsham, United Kingdom | Private equity | Tier 3 | not disclosed | Sterile fill-finish | medium |
| BDD PharmaSmall CDMO/CRO for modified/controlled-release oral formulation dev (proprietary OralogiK). More formulation-dev than commercial scale. | Glasgow, United Kingdom | Private equity | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | low |
| BespakDrug-delivery / combination-product CDMO (pMDI valves, DPI devices, inhaled/nasal). Spun out of Recipharm into a standalone EQT-backed CDMO (2024). | King's Lynn, United Kingdom | Private equityEQT | Tier 3 | not disclosed | Sterile fill-finish | medium |
| Bilthoven BiologicalsVaccine CDMO (inactivated polio, viral-vector/Vero platforms; also mAbs). Owned by Serum Institute of India. | Bilthoven, Netherlands | Family-ownedSerum Institute of India | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Monoclonal antibody | high |
| BimedaIrish family-owned global animal-health company; contract/private-label veterinary manufacturing (drenches, nutritional liquids, ecto-parasiticides). | Dublin, Ireland | Family-owned | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish, Oral solid dose | medium |
| Bioindustria L.I.M.Own + third-party manufacturing. Sterile injectable/freeze-dried solutions and non-sterile tablets/capsules; also an API dept. | Novi Ligure, Italy | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | high |
| BioinovaGMP contract manufacturer of ATMPs — stem-cell/MSC therapies for clinical trials. Spin-off of the Czech Academy of Sciences. | Prague, Czechia | Family-owned | Tier 3 | not disclosed | Cell and gene therapy | high |
| CatSciContract development organisation (route scouting, API/HPAPI process dev, analytical) — the 'D' of CDMO; outsources scale-up. | Cardiff, United Kingdom | Private equityKeensight Capital | Tier 3 | not disclosed | Small-molecule API | low |
| Cell-EasyCell-therapy CDMO (T/NK, MSCs, HSCs; autologous & allogeneic). Proprietary CellReady MSC platform. | Toulouse, France | Family-owned | Tier 3 | not disclosed | Cell and gene therapy | high |
| CellisticiPSC-based cell-therapy CDMO (launched 2022 by Ncardia). Venture-backed. | Gosselies, Belgium | Private equityNcardia | Tier 3 | not disclosed | Cell and gene therapy | medium |
| Celonic | Basel, Switzerland | Family-ownedJRS Group | Tier 3 | n/d | Monoclonal antibody, Biologics and biosimilars, Cell and gene therapy | medium |
| CenexiSterile fill-finish specialist (injectables, ampoules, HPAPI sterile). | Fontenay-sous-Bois, France | Private equityCathay Capital | Tier 3 | €191 m (2023) | Sterile fill-finish | high |
| Cerbios-Pharma~50-year-old CDMO for HPAPIs, ADCs, recombinant proteins and live biotherapeutics; acquired by HAS Healthcare 2025. | Lugano, Switzerland | Private equityHAS Healthcare | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC), Biologics and biosimilars, Microbial and protein | high |
| Chanelle PharmaIreland's largest indigenous generics maker (human + veterinary); explicitly offers CMO/CDMO services alongside own generics. | Loughrea, Ireland | Private equityExponent Private Equity | Tier 3 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish | high |
| ChemConcGMP API / fine-chemical CDMO with high-containment HPAPI/cytotoxic capability; FDA-inspected. | Freiburg, Germany | Family-owned | Tier 3 | not disclosed | Small-molecule API | medium |
| Combino PharmGenerics developer that licenses out dossiers and offers third-party contract manufacturing, mainly via its Malta plant. | Sant Joan Despí, Spain | Family-ownedCorporación Medichem | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Small-molecule API | medium |
| CoripharmaIndependent Icelandic generics CDMO (est. 2018) on the former Actavis site; solid oral dose, specialising in low-volume generics. Geothermal/hydro-powered. | Hafnarfjörður, Iceland | Private equity | Tier 3 | not disclosed | Oral solid dose | high |
| CovexIndependent Spanish API maker since 1977; specialist in vinca alkaloids. CMO/CDMO for third-party API manufacturing. | Colmenar Viejo, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API | high |
| Croma-PharmaFamily-owned hyaluronic-acid specialist that contract-manufactures HA prefilled syringes for ortho/ophthalmology partners. | Leobendorf, Austria | Family-ownedPrinz family | Tier 3 | not disclosed | Sterile fill-finish | medium |
| CuridaFrom a 2015 buyout of Takeda's Elverum sterile-liquids plant. BFS + nasal-spray fill-finish CDMO, plus a small Bio-CDMO unit (mAbs for preclinical/diagnostic use). | Elverum, Norway | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars | high |
| Custom Pharma ServicesFull-service oral-solid-dose CDMO (tablets/capsules/powders incl. HPAPI); process dev through commercial. Est. 1979. | Hove, United Kingdom | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| DeretilGlobal leader in side chains for beta-lactam antibiotics; custom synthesis/enzymatic chiral tech. Founded 1961. | Cuevas del Almanzora, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API, Microbial and protein | high |
| ErregierreFamily company (1974) making small/medium-volume APIs (human + veterinary); contract manufacturing + DMF/CEP support. | San Paolo d'Argon, Italy | Family-ownedGargani family | Tier 3 | not disclosed | Small-molecule API | high |
| EscolitNewer (2021) Lithuanian CMO/CDMO for medicines and supplements — three full-cycle EU-GMP lines. Early stage; contract track record still thin. | Telšiai, Lithuania | Family-owned | Tier 3 | not disclosed | Oral solid dose | low |
| eTheRNA immunotherapiesVenture-backed RNA/mRNA-LNP firm offering contract dev/manufacturing; positions as tech partner. Financial restructuring reported. | Niel, Belgium | Private equity | Tier 3 | not disclosed | mRNA and LNP | low |
| EVER PharmaSpecialty-injectables pharma that also runs a full CDMO for complex sterile injectables (cytotoxics, hormones, suspensions). | Unterach, Austria | Family-ownedB.F.H. Privatstiftung | Tier 3 | not disclosed | Sterile fill-finish | medium |
| eXmoor PharmaIndependent full-service cell & gene therapy CDMO + CMC consultancy. | Bristol, United Kingdom | Private equityMVM Partners | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine, Biologics and biosimilars | medium |
| FaveaFamily-run CDMO for nutraceuticals plus human/veterinary solid dosage (tablets, capsules, pellets). Pharma scope modest vs. supplements. | Kopřivnice, Czechia | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| GalenicaPrivately owned Swedish CDMO (est. 1999); dev + GMP manufacture of solids, liquids, semi-solids, small molecules and peptides incl. high-potency. | Malmö, Sweden | Family-owned | Tier 3 | not disclosed | Oral solid dose, Peptide, Small-molecule API | high |
| GP PharmCDMO focused on highly complex injectables: peptides, oligonucleotides, hormones, liposomes and microspheres. FDA-inspected. | Sant Quintí de Mediona, Spain | Family-ownedParente family | Tier 3 | not disclosed | Peptide, Sterile fill-finish | high |
| HALIXMammalian biologics CDMO: viral vectors, vaccines, recombinant proteins (1,000L SUB). Made AstraZeneca's COVID vaccine. | Leiden, Netherlands | Family-ownedDroege Group | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Monoclonal antibody | high |
| HAS Healthcare Advanced SynthesisEx-Helsinn HPAPI/anticancer API CDMO spun out as independent in 2022; now parent of Cerbios. | Biasca, Switzerland | Family-ownedBraglia family | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC) | high |
| Hermes PharmaCDMO specialised in user-friendly oral forms: effervescent, orally-disintegrating granules, lozenges, instant drinks. | Wolfratshausen, Germany | Family-ownedHermes Arzneimittel | Tier 3 | not disclosed | Oral solid dose | medium |
| HiTech HealthFirst Irish company licensed to contract-manufacture cell & gene therapies. End-to-end ATMP CDMO with EU/UK QP release. | Galway, Ireland | Family-owned | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine, Biologics and biosimilars | high |
| Iasis PharmaProvides CDMO/CMO services alongside own products (since 1985). Broad dosage forms; exports to 36 countries. | Koropi, Greece | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | high |
| IBI LorenziniAseptic manufacturing of sterile injectables (specialist in sterile penicillins/cephalosporins) plus oral, topical and biotech. | Aprilia, Italy | Family-ownedIbigen Group | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Monoclonal antibody, Peptide | high |
| IcosagenEnd-to-end mammalian biologics CRDMO: antibody discovery/engineering, CHO cell-line/process dev, and a new GMP facility (50–1000L single-use) for Phase I/II drug substance. | Tartu, Estonia | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody | high |
| IMUNA PHARMContract manufacturer of sterile infusion and dialysis solutions in single/multi-chamber bags; own brands plus products for multinationals. | Šarišské Michaľany, Slovakia | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| InnoCore PharmaceuticalsDrug-delivery CDMO for long-acting injectables (microspheres, implants, depot gels) via proprietary SynBiosys polymers. | Groningen, Netherlands | Family-owned | Tier 3 | not disclosed | Peptide, Biologics and biosimilars, Sterile fill-finish | high |
| KeveltEU-GMP Estonian maker of sterile small-volume parenterals, sterile semi-solids and biological medicinal products; seeks contract-manufacturing partnerships. | Tallinn, Estonia | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Biologics and biosimilars | high |
| Klocke Pharma-ServiceContract manufacturing/packaging of solid dosage plus aseptic liquids and lyophilisates. | Appenweier, Germany | Family-ownedKlocke Gruppe | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Laboratoires SteropSterile injectables/ampoules maker (est. 1947); own essential-medicines portfolio plus CMO services. ~75% export. | Brussels, Belgium | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| Laboratórios BasiPortuguese pharma (since 1956) offering contract manufacturing for injectables, gels, creams and oral solutions. CMO secondary. | Mortágua, Portugal | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | medium |
| Lamp San ProsperoItalian oral-solid-dose CDMO. Non-biologics tier-3 addition for completeness. | San Prospero, Italy | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | medium |
| Losan PharmaCDMO for solids, semi-solids, liquids, sachets and effervescent forms; FDA/ANVISA inspected. | Neuenburg am Rhein, Germany | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| LusomedicamentaManufacturer of solid, liquid and semi-solid dosage forms; explicitly lists contract manufacturing. Exports to 47 countries. | Queluz, Portugal | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| MedinfarOperates a CMO/CDMO industrial unit (~20 yrs) alongside its own portfolio; finished dosage forms, galenic, packaging. | Amadora, Portugal | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Meditop PharmaceuticalFamily-owned Hungarian SME making solid forms with own R&D; lists contract manufacturing but primarily own-product. | Pilisborosjenő, Hungary | Family-owned | Tier 3 | not disclosed | Oral solid dose | low |
| Micro-SphereFounder-led CDMO specialising in spray drying (poorly-soluble drugs) and capsule filling, clinical to commercial. | Monteggio, Switzerland | Family-owned | Tier 3 | not disclosed | Oral solid dose, Small-molecule API | high |
| Miltenyi BioindustryCDMO division of Miltenyi Biotec for lentiviral vectors and cell/gene therapies (supplied LVV for Adaptimmune TECELRA). | Bergisch Gladbach, Germany | Family-ownedMiltenyi Biotec | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine | low |
| NextPharma GöttingenGerman solid-dosage sites (incl. allphamed Pharbil) of the privately held European NextPharma group. | Göttingen, Germany | Private equity | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | low |
| Northway BiotechCEE cost-competitive biologics CDMO scaling to 5,000 L stainless steel. | Vilnius, Lithuania | Family-owned | Tier 3 | n/d | Monoclonal antibody, Microbial and protein, Biologics and biosimilars, Sterile fill-finish, Viral vector and vaccine, Cell and gene therapy | medium |
| Nova LaboratoriesIndependent aseptic-processing CDMO + 'Specials' supplier; sterile fill-finish for clinical-trial medicines. | Leicester, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars, Microbial and protein | medium |
| Ovelle PharmaceuticalsFamily-owned (since 1934). Own dermatology brands plus CMO/CDMO manufacturing of cosmetic, medical-device and licensed products. | Dundalk, Ireland | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | medium |
| Palla Pharma NorwayNorwegian maker of opiate-based APIs and finished dose (est. 1949). Primarily a merchant/own-product opiate-API producer rather than a client-driven CDMO. | Kragerø, Norway | Family-owned | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | low |
| Paras BiopharmaceuticalsFounder-led microbial-biologics CDMO: recombinant biologics/biosimilars in microbial systems, plus peptides and proteins. Scales 10L→750L+. | Oulu, Finland | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Peptide | medium |
| Pharma ProductionSmall Norwegian CDMO/CMO; contract manufacturing of licensed medicines, IMPs and placebo, plus QC/QP release. Non-sterile fluid/semi-solid forms outside the code set. | Oslo, Norway | Family-owned | Tier 3 | not disclosed | Other dose forms | high |
| Pharma-SkanIndependent CMO producing/filling liquid and sterile pharmaceuticals and oral liquids for human and veterinary use. | Skanderborg, Denmark | Private equityBrygge Partners | Tier 3 | not disclosed | Sterile fill-finish | medium |
| PharmatoryFinnish CDMO: small-molecule synthesis, process R&D, cGMP API contract manufacturing and analytics for human and veterinary pharma. | Oulu, Finland | Private equityMB Funds | Tier 3 | not disclosed | Small-molecule API | high |
| PharmpurIndependent family-owned contract manufacturer of sterile liquids in syringes/vials (ophthalmic focus). | Königsbrunn, Germany | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | low |
| Polpharma BiologicsJune 2025 demerger: biosimilars brand stays as Polpharma Biologics (operating from Switzerland); the CDMO becomes Rezon Bio. | Gdańsk, Poland | Family-ownedPolpharma | Tier 3 | ~US$18–100 m est. | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | low |
| Polymun ScientificFamily-owned biopharma/liposome-LNP CDMO; scaled the LNP process for the BioNTech/Pfizer Comirnaty vaccine. | Klosterneuburg, Austria | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine | high |
| PrasfarmaCMO/CDMO specialized in cytostatics, HPAPI and oncology; aseptic fill/lyophilization plus solid forms. Annex-1. | Cerdanyola del Vallès, Spain | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose | high |
| Praxis PharmaceuticalCDMO for dev + contract manufacturing of liquid and lyophilised sterile injectables incl. biologics and orphan drugs. Annex-1. | Vitoria-Gasteiz, Spain | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | high |
| ProBioGenIndependent biologics CDMO (proteins/antibodies, viral vectors, vaccines); Charité spin-off, founded 1994. | Berlin, Germany | Family-owned | Tier 3 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Viral vector and vaccine | medium |
| PSMFamily-run aseptic fill-and-finish CDMO; new facility passed EU GMP Annex 1. | Schiffweiler, Germany | Family-ownedTrennheuser family | Tier 3 | not disclosed | Sterile fill-finish | medium |
| Purna PharmaceuticalsNon-sterile CDMO: solids, semi-solids and liquids; OEB 1-5. | Puurs, Belgium | Private equityAmpersand Capital | Tier 3 | not disclosed | Oral solid dose | high |
| Quality ChemicalsIndependent Spanish CDMO (40+ yrs) specializing in inorganic/organic salts in API and excipient grades. GMP/ISO. | Esparreguera, Spain | Family-owned | Tier 3 | not disclosed | Small-molecule API | high |
| Rezon BioCDMO carved out of Polpharma Biologics (June 2025); positions to be Europe's most cost-competitive CDMO. | Gdańsk, Poland | Family-ownedPolpharma | Tier 3 | n/d | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | low |
| Richter BiologicsGerman microbial/biologics CDMO. | Hamburg, Germany | Family-owned | Tier 3 | n/d | Biologics and biosimilars, Microbial and protein | low |
| Richter PharmaFamily pharma group with a GMP contract-manufacturing unit for injectable solutions and semi-solids. | Wels, Austria | Family-owned | Tier 3 | not disclosed | Sterile fill-finish | medium |
| Rosemont PharmaceuticalsOral-liquid-medicines specialist (~60 yrs); primarily branded/specials but offers contract manufacturing/CDMO services. | Leeds, United Kingdom | Private equityInflexion | Tier 3 | not disclosed | Small-molecule API, Oral solid dose | medium |
| RoslinCTAdvanced-therapy (cell & gene) CDMO spun out of the Roslin Institute. Manufactures CASGEVY, first FDA-approved CRISPR gene therapy. | Edinburgh, United Kingdom | Private equityGHO Capital / Pioneer Group | Tier 3 | not disclosed | Cell and gene therapy | high |
| S.A.L.F. Laboratorio FarmacologicoInjectable/infusion sterile solutions (ampoules, bottles, bags) — own portfolio plus explicit contract manufacturing. Since 1921. | Cenate Sotto, Italy | Family-ownedAngeletti family | Tier 3 | not disclosed | Sterile fill-finish | high |
| Sanochemia PharmazeutikaCDMO for sterile injectables and small-molecule APIs; also a leading MRI/CT contrast-agent maker. | Neufeld an der Leitha, Austria | Private equityEOSS Industries consortium | Tier 3 | not disclosed | Small-molecule API, Sterile fill-finish | high |
| ScanpharmGMP family-owned combined CMO and contract laboratory (est. 1951); tablets incl. packaging, serialization, testing; small own niche-generics portfolio. | Birkerød, Denmark | Family-owned | Tier 3 | not disclosed | Oral solid dose | high |
| SkyepharmaComplex oral-solid-dose specialist (modified-release, multi-layer/press-coated tablets). Management-owned. | Saint-Quentin-Fallavier, France | Family-ownedOléron Pharma | Tier 3 | ~€20 m+ (site) | Oral solid dose | high |
| Sterling Pharma | Cramlington, United Kingdom | Private equityGHO Capital | Tier 3 | ~£130 m FY2023 | Small-molecule API, Antibody-drug conjugate (ADC), Peptide | medium |
| Symbiosis Pharmaceutical ServicesIndependent sterile aseptic fill-finish CDMO (clinical + commercial): mAbs, ATMPs, viral vectors, ADCs, vaccines. FDA-inspected. | Stirling, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Antibody-drug conjugate (ADC), Biologics and biosimilars, Cell and gene therapy, Small-molecule API | medium |
| SyVento BioTechGreenfield mRNA/LNP CDMO; MIA obtained 31 July 2025. | Skawina, Poland | Family-owned | Tier 3 | early-stage | mRNA and LNP | low |
| ten23 healthSterile drug-product formulation & fill-finish CDMO (biologics, cell & gene therapy); absorbed swissfillon (Visp) in 2021. | Basel, Switzerland | Private equity3i Group | Tier 3 | not disclosed | Sterile fill-finish, Biologics and biosimilars, Cell and gene therapy | high |
| TouchlightCDMO making enzymatic 'doggybone DNA' (dbDNA) as template for mRNA/viral-vector/genetic medicines. First synthetic-DNA maker with MHRA GMP API cert. | London, United Kingdom | Private equity | Tier 3 | not disclosed | Cell and gene therapy, mRNA and LNP, Viral vector and vaccine | medium |
| Upperton Pharma SolutionsSpray-drying specialist CDMO: formulation + dosage-form dev for oral, nasal, pulmonary and sterile forms (small molecules + biologics). | Nottingham, United Kingdom | Private equityInflexion | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | high |
| ValentisLithuanian group offering contract manufacturing of tablets, capsules, liquids/shots and powders plus primary/secondary packaging. | Kaunas, Lithuania | Family-owned | Tier 3 | not disclosed | Oral solid dose | medium |
| Wasdell GroupUK contract packaging + CDMO (solid/non-sterile dosage, clinical + commercial). Wound down Irish operations in 2024 — verify current status. | Swindon, United Kingdom | Family-owned | Tier 3 | not disclosed | Oral solid dose, Sterile fill-finish | medium |
| Wellgem BiopharmaBiologics contract dev/manufacturing: mammalian + microbial cell-line/process dev, cGMP cell banking, Phase II pilot facility. Newer entrant. | Vilnius, Lithuania | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Viral vector and vaccine, Cell and gene therapy | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)
By ownership
- Privately owned CDMOs in Europe
- Family-owned CDMOs in Europe (101)
- Private-equity-owned CDMOs in Europe (54)